GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Gross Margin %

Viva Biotech Holdings (HKSE:01873) Gross Margin % : 32.81% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Viva Biotech Holdings's Gross Profit for the six months ended in Dec. 2023 was HK$364 Mil. Viva Biotech Holdings's Revenue for the six months ended in Dec. 2023 was HK$1,108 Mil. Therefore, Viva Biotech Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was 32.81%.

Warning Sign:

Viva Biotech Holdings gross margin has been in long-term decline. The average rate of decline per year is -9%.


The historical rank and industry rank for Viva Biotech Holdings's Gross Margin % or its related term are showing as below:

HKSE:01873' s Gross Margin % Range Over the Past 10 Years
Min: 30.94   Med: 46   Max: 58.14
Current: 34.26


During the past 8 years, the highest Gross Margin % of Viva Biotech Holdings was 58.14%. The lowest was 30.94%. And the median was 46.00%.

HKSE:01873's Gross Margin % is ranked worse than
75.33% of 750 companies
in the Biotechnology industry
Industry Median: 60.91 vs HKSE:01873: 34.26

Viva Biotech Holdings had a gross margin of 32.81% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Viva Biotech Holdings was -9.00% per year.


Viva Biotech Holdings Gross Margin % Historical Data

The historical data trend for Viva Biotech Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Gross Margin % Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 48.25 43.74 30.94 34.28 34.26

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.06 31.11 37.04 35.54 32.81

Competitive Comparison of Viva Biotech Holdings's Gross Margin %

For the Biotechnology subindustry, Viva Biotech Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Gross Margin % falls into.



Viva Biotech Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Viva Biotech Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=807.7 / 2357.726
=(Revenue - Cost of Goods Sold) / Revenue
=(2357.726 - 1550.045) / 2357.726
=34.26 %

Viva Biotech Holdings's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=363.6 / 1108.429
=(Revenue - Cost of Goods Sold) / Revenue
=(1108.429 - 744.787) / 1108.429
=32.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Viva Biotech Holdings  (HKSE:01873) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Viva Biotech Holdings had a gross margin of 32.81% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Viva Biotech Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings (HKSE:01873) Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines